TheraPten Biosciences

TheraPten Biosciences Overview

Founded 2016
Status Private
Latest Deal Type Early Stage VC
Latest Deal Amount $2M
Latest Deal Amount
Investors 1

TheraPten Biosciences General Information


Provider of pre clinical biotechnological research and development services intended to develop naturally-occurring anti-cancer therapeutic protein. The company's pre clinical biotechnological research and development services are focused in development of potent tumor suppressor proteins that are functionally inactivated in many human cancers, enabling client to find a treatment of cancer related diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 101-1865 Dilworth Drive
  • Suite 705
  • Kelowna, British Columbia V1Y 9T1
  • Canada
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TheraPten Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 16-Jul-2018 $2M 000 Completed Startup

TheraPten Biosciences Executive Team (3)

Name Title Board Seat Contact Info
Nassos Alevizopoulos Ph.D Co-Founder, Chairman & Chief Executive Officer
Harvey Lalach Co-Founder, Director & Chief Business Officer
Ramon Parsons MD Co-Founder & Scientific Advisor

TheraPten Biosciences Board Members (1)

Name Representing Role Since
Nassos Alevizopoulos Ph.D TheraPten Biosciences Co-Founder, Chairman & Chief Executive Officer 000 0000

TheraPten Biosciences Investors (1)

To view TheraPten Biosciences‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Columbia Technology Ventures University Minority 000 0000 000000 0

Ready to get started?

Request a free trial